Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 May 2020 | Story Leonie Bolleurs | Photo Supplied
Prof Das Steÿn was announced as the recipient of the prestigious Stals Prize this week (19 May 2020), awarded by the Suid-Afrikaanse Akademie vir Wetenskap en Kuns.

Prof Das Steÿn, former Head and currently a research fellow in the Department of Urban and Regional Planning at the University of the Free State (UFS), has been named the recipient of the prestigious Stals Prize this week (19 May 2020), awarded by the Suid-Afrikaanse Akademie vir Wetenskap en Kuns (South African Academy for Science and Arts).

The current Head of the Department, Prof Maléne Campbell, together with two academics from the North-West University, Profs Juanée Cilliers (Head of the Urban and Regional Planning group) and Ewert Kleynhans (School of Economic Sciences), nominated Prof Steyn for the award.

A lifetime’s work

The Stals Prize for Urban and Regional Planning was awarded to Prof Steÿn, based on his numerous publications in Afrikaans, the important role he played in the planning profession in South Africa, his major contribution to the planning of literature, as well as the academic development of urban and regional planning. The award recognises Prof Steÿn for a lifetime's work in the field of urban and regional planning – including his appointment as a lecturer (1980-2009) and also for his time as editor of the journal Stads-en Streekbeplanning / Town and Regional Planning / Meralo ya Ditoropo le Mabatowa (2000-2019).

“As editor of the journal for Urban and Regional Planning, Prof Steÿn set a very high standard. So much so that this UFS journal was listed earlier this year on the international SciELO (Scientific Electronic Library Online), a Norwegian database. As an academic, his research and theoretical knowledge of normative planning are also highly regarded,” says Prof Campbell.

Motivating Prof Steÿn’s nomination for the Stals Prize, Prof Campbell states that as editor, he has sought to highlight issues in the South African planning industry through well-founded headlines. “The journal also grew from a small local journal to a journal that is being read every month in more than 60 countries on the free access platform,” she adds.

In addition to this journal, Prof Steÿn has also published in other journals and written books that have appeared bilingually in South Africa. Then there is also a work that has appeared in Dutch in the Netherlands with his contribution in Afrikaans.

He applied a combination of the urbanistic concept with Christian philosophy in his work and published some articles on the topic.

Distinction between thought and action

Prof Steÿn says that in urbanistics, a distinction is made between the framework of thought and action. It is a matter of answering the ‘what?’, ‘how?’, and ‘why?’ questions.

He believes urbanistics is particularly useful in public participation to bring the various role players in planning together. It makes it possible to distinguish between the considerable number of factors that complicate matters. South Africa, with its unique situation regarding planning, may be able to make good use of this concept.

As example, he uses the matter of providing basic services such as electricity to a community. “At the first level of infrastructure, the problem of providing electricity is easy to solve: x people use y units, implying that z units must be provided. This solves the ‘what?’ part of the problem. The ‘how?’ question in the superstructure is also relatively easy to answer. Different engineers may have different solutions about the appropriate design of the distribution network and how it should link to the greater whole. Still, in the end, the most effective design will be sufficient.”
 
“The major crisis is in the ‘why?’ question. At the ideological level, basic services mean different things to different people. Basic services to the Marxist are a right that every person must receive free of charge, while the capitalist considers it a commodity that every human being should pay for to receive.”

“This simple example shows that there is a definite difference in viewpoints about the mere provision of electricity and that these attitudes of people will, as a matter of course, influence the planning process itself,” he explains. 

Recognising outstanding work

The Suid-Afrikaanse Akademie vir Wetenskap en Kuns awards the Stals Prize for, among others, high-quality publications or a series of high-quality publications (preferably in Afrikaans) whereby extraordinary contributions are made to the practice of science.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept